

TITLE

Neutralizing antibody responses to SARS-CoV-2: a population based seroepidemiological analysis in Delhi, India

AUTHORS

1. Pragya Sharma

Maulana Azad Medical College, New Delhi

2. Ekta Gupta

Institute of Liver and Biliary Sciences, New Delhi

3. Saurav Basu

Maulana Azad Medical College, New Delhi ; Indian Institute of Public Health - Delhi

4. Reshu Aggarwal

Institute of Liver and Biliary Sciences, New Delhi

5. Suruchi Mishra (Corresponding Author)

Maulana Azad Medical College, New Delhi

6. Pratibha Kale

Institute of Liver and Biliary Sciences, New Delhi

7. Nutan Mundeja

Directorate General Health Services, Government of NCT, Delhi

8. B S Charan

Directorate General Health Services, Government of NCT, Delhi

9. Gautam Kumar Singh

Directorate General Health Services, Government of NCT, Delhi

10. Mongjam Meghachandra Singh

Maulana Azad Medical College, New Delhi

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

We conducted this study to estimate seroprevalence of neutralizing antibodies in the general population and to further correlate it with the IgG SARS-CoV-2 IgG levels. This present cross-sectional analysis was conducted as a sequel to a state level community-based seroepidemiological study in Delhi, India. A total of 2564 seropositive samples were selected from 25622 seropositive samples through simple random sampling. Neutralizing capacity was estimated by performing a surrogate virus neutralization test with the sVNT (GenScript) assay. Neutralizing antibody against the SARS-CoV-2 virus was operationally considered as detected when the signal inhibition was $\geq 30\%$.

A total of 2233 (87.1%, 95% C.I. 85.7, 88.3) of the 2564 SARS-CoV-2 seropositive samples had detectable neutralizing antibodies. On bi-variate analysis but not on adjusted analysis, Covid-19 vaccination showed a statistically significant association with the presence of neutralizing antibodies ($p < 0.001$). The signal/ cut off (S/CO) of SARS-CoV-2 IgG ranged from 1.00 to 22.8 (median 11.40). In samples with $S/CO \geq 4.00$, the neutralizing antibodies ranged from 94.5 to 100%, while in samples with $S/CO < 4.00$, it ranged from 52.0 to 79.2%. The neutralizing antibody seroprevalence strongly correlated with the S/CO range ($r = 0.62$, $p = 0.002$). In conclusion, in populations with high SARS-CoV-2 seroprevalence, neutralizing antibodies are generated in nearly 9 of 10 seropositive individuals.

Keywords

SARS-CoV-2; Neutralizing antibody; Vaccination; Covid-19

INTRODUCTION

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with enormous morbidity, mortality, and economic losses. Till date, India has recorded 34,633,255 cases and 473,326 deaths [1].

Protection from SARS-CoV-2 infection is accorded through previous infection or vaccination that substantially reduces the risk of symptomatic and severe disease and that of reinfection [2, 3]. Neutralizing SARS-CoV-2 antibodies once produced are likely to provide durable and effective protection at-least several ensuing months [4].

Several population-based SARS-CoV-2 seroepidemiological studies have been conducted in India. However, these studies primarily focussed on screening antibodies in the participants through antibodies recognizing SARS-CoV-2 spike antigens and/or nucleoprotein [5, 6]. Consequently, it is important to identify the extent to which these populations have also developed protective neutralization antibodies.

This study was therefore conducted with the objective of estimating the seroprevalence of neutralizing antibodies in the general population and to further correlate it with the IgG SARS-CoV-2 IgG levels.

METHODS

This present cross-sectional analysis was conducted as a sequel to a state level community-based seroepidemiological study which estimated the seroprevalence of IgG SARS-CoV-2 in Delhi, India during August-September 2021. A total of 25,622 (89.6%) of the 28,602 samples had detectable IgG antibodies. The VITROS® assay on VITROS® 3600 (Ortho Clinical Diagnostics, Raritan, NJ, USA) based on chemiluminescent technology having 90% sensitivity and 100% specificity was used for this purpose [7]. The detailed methodology and sampling strategy of the study are being reported elsewhere (preprint).

We conducted screening for neutralizing antibodies against the SARS-CoV-2 virus in 10% of the seropositive samples (n=2564) representing the entire range of signal to cut off (S/CO). The samples for screening were selected through computer-based simple random sampling method. This sample size was adequate at 95% confidence levels with 1.2% absolute precision levels.

Neutralizing capacity was estimated by performing a surrogate virus neutralization test (sVNT) (GenScript, Piscataway, NJ, USA) as per the manufacturers' instructions. The sVNT kit detects

circulating neutralizing anti SARS-CoV-2 antibodies through immune system response either after COVID-19 infection or vaccination. These antibodies prevent the interaction between the ACE2 human cell surface receptor and the receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein [8]. Neutralizing antibody to SARS-CoV-2 was operationally considered as detected when the signal inhibition was $\geq 30\%$.

Data were analysed with IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp. A p-value < 0.05 was considered statistically significant

The study was approved by the Institutional Ethics Committee, Maulana Azad Medical College & Associated Hospitals, New Delhi vide F.1/IEC/MAMC/85/03/2021/No428 dated 21.08.2021. Electronic and informed consent was obtained from all the study participants.

RESULTS AND DISCUSSION

A total of 2233 (87.1%, 95% C.I. 85.7, 88.3) of the 2564 SARS-CoV-2 seropositive samples were observed to be having detectable neutralizing antibodies. On bi-variate analysis but not on adjusted analysis, Covid-19 vaccination showed a statistically significant association with the presence of neutralizing antibodies ($p < 0.001$) (Table 1).

The signal/ cut off (S/CO) of SARS-CoV-2 IgG ranged from 1.00 to 22.8 (median 11.40). Among the samples with $S/CO \geq 4.00$, the prevalence of neutralizing antibodies ranged from 94.5 to 100%, while in samples with $S/CO < 4.00$, it ranged from 52.0 to 79.2% (Table 2). The neutralizing antibody seroprevalence strongly correlated with the S/CO range ($r = 0.62$, $p = 0.002$)

Previous studies have suggested that neutralizing antibodies to SARS-CoV-2 are able to block the viral infection and provide durable immune response despite the likelihood of waning of overall antibody levels. A large-scale study at Mount Sinai hospital, USA among health care workers also found strong correlation of immunoglobulin G antibody responses against the viral spike protein generated in those with natural SARS-CoV-2 infection [9]. Our study results further indicate that in the populations with high SARS-CoV-2 seroprevalence, neutralizing antibodies are generated in nearly 9 of 10 seropositive individuals, with no statistically significant variation in the observed risk based on their age, sex, and comorbidity status.

This study also suggests that a higher signal to cut-off ratio may be considered as an indirect predictor for the presence of neutralizing antibody response. This finding may have a clinical

implication towards recommending booster doses in vulnerable populations such as the immunocompromised and healthcare workers.

Certain variants of concern especially the Delta have demonstrated the ability to bypass existing immune response and elicit symptomatic disease even in vaccinated and more rarely in recovered individuals [10]. However, in this study, vaccination with at-least one dose of vaccine, either CHADOX1 NCOV-19 (Covishield) or BBV152 (Covaxin) was likely to induce robust neutralizing antibody response.

Sources of funding: This research received no specific funding from any agency in the public, commercial or not-for-profit sectors. The logistics and human resources were deputed by the Directorate General of Health Services, government of the National Capital Territory, Delhi and supported by the ATE Chandra Foundation and ACT grants.

Acknowledgments: We thank all the district Nodal officers of Delhi for facilitating the data and sample collection. We express thanks to the ATE Chandra Foundation and ACT grants, and the IDFC Foundation for technical support. We also thank Ms. Arti Kakkar for her assistance with data management for this investigation.

REFERENCES

1. John Hopkins Coronavirus Tracker. <https://coronavirus.jhu.edu/map.html>. Last Accessed: 05.12.2021
2. Suthar MS, Zimmerman MG, Kauffman RC, et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. *Cell Rep Med*. 2020;1(3):100040.
3. Edara VV, Hudson WH, Xie X, Ahmed R, Suthar MS. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination. *JAMA*. 2021 May 11;325(18):1896-1898.
4. Dan JM, Mateus J, Kato Y, et al. . Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science*. 2021;371(6529):eabf4063.
5. Prevalence of SARS-CoV-2 infection in India: findings from the national serosurvey, May-June 2020. Murhekar MV, Bhatnagar T, Selvaraju S, et al. *Indian J Med Res*. 2020;152:48–60
6. Sharma N, Sharma P, Basu S, et al. Second Wave of the COVID-19 Pandemic in Delhi, India: High Seroprevalence Not a Deterrent?. *Cureus*. 2021;13(10):e19000. Published 2021 Oct 24. doi:10.7759/cureus.19000
7. Instructions for use - CoV2G. VITROS.<https://www.fda.gov/media/137363/download> 2021
8. GenScript. SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit (RUO). <https://www.genscript.com/covid-19-detection-svnt.html> (Accessed December 14 2021)
9. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science*. 2020 Dec 4;370(6521):1227-1230.
10. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature*. 2021;596(7871):276-280.

Table 1. Factors associated with positive neutralization antibodies (N=2564)

Variable	Total*	Neutralizing Ab present	Adjusted odds	p-value
Age				
<18	487	403 (82.8)	1.1 (0.77, 1.57)	0.59
≥18	2077	1830 (81.1)	1	
Sex				
Male	1093	944 (86.4)	1	0.84
Female	1467	1286 (87.7)	1 (0.78, 1.3)	
History Covid-19				
Present	559	495 (88.6)	1.1 (0.83, 1.5)	0.40
Absent	1300	1117 (85.9)	1	
HTN				
Yes	173	148 (85.5)	1	0.35
No	1686	1464 (86.8)	1.2 (0.77, 2.1)	
DM				
Yes	119	101 (84.9)	1	0.58
No	1740	1511 (86.8)	1.2 (0.66, 2.1)	
Vaccine doses				
0 dose	929	769 (82.8)	1	0.09
1 dose	430	400 (93.0)	2.1 (0.7, 6.0)	
2 doses	500	443 (88.6)	1.7 (0.5, 3.2)	
Vaccine type				
BBV152	185	164 (88.6)	1	0.49
CHADOX1 NCOV-19	742	676 (91.1)	1.2 (0.7, 2.0)	

*Not equal to 2564 due to missing questionnaire data

Table 2. S/CO Range and neutralization antibody positivity

S/CO range	Total samples tested	Total samples positive for neutralization antibody	Percentage of samples positive for neutralization antibody (%)
1.00 to 1.99	446	232	52
2.00 to 2.99	309	237	76.7
3.00 to 3.99	111	88	79.2
4.00 to 4.99	109	103	94.5
5.00 to 5.99	109	105	96.3
6.00 to 6.99	110	105	95.5
7.00 to 7.99	110	109	99
8.00 to 8.99	110	109	99
9.00 to 9.99	110	110	100
10.00 to 10.99	111	111	100
11.00 to 11.99	110	109	99
12.00 to 12.99	111	111	100
13.00 to 13.99	110	109	99
14.00 to 14.99	111	111	100
15.00 to 15.99	110	109	99
16.00 to 16.99	110	110	100
17.00 to 17.99	111	111	100
18.00 to 18.99	59	59	100
19.00 to 19.99	49	47	96
20.00 to 20.99	20	20	100
21.00 to 21.99	19	19	100
22.00 to 22.8	09	09	100
Total	2564	2233	87.1